InvestorsHub Logo
Followers 32
Posts 19830
Boards Moderated 0
Alias Born 07/10/2015

Re: boston745 post# 32313

Friday, 09/18/2020 6:28:45 PM

Friday, September 18, 2020 6:28:45 PM

Post# of 40903
Amylin Pharma shows that companies can regain lost value from revenue loss when IPR&D is able to continue and is valuable.

IPR&D at Sintx has so many lucrative markets it can play in that its market potential is larger than all Amylin drugs combined. Of course Sintx cant get there by itself which is why its relationships with Zimmer Biomet & Morgan Ceramics are such big deals, particularly from a commercialization standpoint. These relationships further justify a valuation greater than 225m.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SINT News